Is BioCryst a Good Stock to Buy Now?

Shares of BioCryst (NASDAQ: BCRX) have climbed by around 180% since the company's first rare-disease drug earned FDA approval in December. And another potential blockbuster rolling through the company's pipeline has the potential to be an even bigger winner.

Yet despite strong gains over the past six months, BioCryst's market cap is still lower than the market caps of many clinical-stage biotech companies. Is this drugmaker positioned to keep delivering big gains for investors, or is its stock cheap for a good reason?

Image source: Getty Images.

Continue reading

Source Fool.com